Huxley SANSA Home Sleep Apnea Test (1000-00) vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent in their application of AI within cardiology but address distinct diagnostic needs. Huxley SANSA is designed for home sleep apnea and cardiac arrhythmia diagnosis via a wearable patch, offering remote monitoring capabilities. In contrast, Ultromics' EchoGo Amyloidosis analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis within a clinical imaging workflow.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Huxley SANSA is an FDA-cleared, AI-powered wearable patch for home sleep apnea and cardiac arrhythmia diagnosis. EchoGo Amyloidosis is the first FDA-cleared AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Huxley SANSA uses a wearable chest patch to collect 9 physiological data channels, including ECG and SpO2, with data uploaded via built-in cellular capability. EchoGo Amyloidosis analyzes 2D echocardiogram video clips, specifically a single apical 4-chamber view.
Huxley SANSA is designed for use in Cardiology, Pulmonology, and Sleep Medicine, bridging the gap between cardiology and sleep. EchoGo Amyloidosis is intended for Cardiology, specifically to assist in identifying patients at risk of cardiac amyloidosis.
Huxley SANSA offers an app-free workflow with built-in cellular data upload for streamlined patient care. EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, such as PACS, DICOM, and HL7.
Huxley SANSA provides AI-powered auto-scoring algorithms for sleep apnea and cardiac arrhythmia diagnosis, generating an automated report on the Huxley HUB. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis.
Huxley SANSA has been validated against polysomnography (PSG) and achieved 88% sensitivity and 87% specificity for detecting moderate-to-severe OSA. EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity for detecting cardiac amyloidosis.